Cipla Management

Management criteria checks 3/4

Cipla's CEO is Umang Vohra, appointed in Sep 2016, has a tenure of 7.83 years. total yearly compensation is ₹174.90M, comprised of 45.7% salary and 54.3% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth ₹509.34M. The average tenure of the management team and the board of directors is 5.3 years and 9.3 years respectively.

Key information

Umang Vohra

Chief executive officer

₹174.9m

Total compensation

CEO salary percentage	45.7%
CEO tenure	7.8yrs
CEO ownership	0.04%
Management average tenure	5.3yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Umang Vohra's remuneration changed compared to Cipla's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	₹41b
Dec 31 2023	n/a	n/a	₹37b
Sep 30 2023	n/a	n/a	₹35b
Jun 30 2023	n/a	n/a	₹31b
Mar 31 2023	₹175m	₹80m	₹28b
Dec 31 2022	n/a	n/a	₹26b
Sep 30 2022	n/a	n/a	₹26b
Jun 30 2022	n/a	n/a	₹25b
Mar 31 2022	₹229m	₹75m	₹25b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹26b
Jun 30 2021	n/a	n/a	₹25b
Mar 31 2021	₹181m	₹20m	₹24b
Dec 31 2020	n/a	n/a	₹22b
Sep 30 2020	n/a	n/a	₹18b
Jun 30 2020	n/a	n/a	₹16b
Mar 31 2020	₹136m	₹20m	₹15b
Dec 31 2019	n/a	n/a	₹17b
Sep 30 2019	n/a	n/a	₹16b
Jun 30 2019	n/a	n/a	₹16b
Mar 31 2019	₹150m	₹20m	₹15b
Dec 31 2018	n/a	n/a	₹13b
Sep 30 2018	n/a	n/a	₹14b
Jun 30 2018	n/a	n/a	₹15b
Mar 31 2018	₹189m	₹20m	₹14b

Compensation vs Market: Umang's total compensation ($USD2.09M) is above average for companies of similar size in the Indian market ($USD1.16M).

Compensation vs Earnings: Umang's compensation has been consistent with company performance over the past year.

CEO

Umang Vohra (53 yo)

7.8yrs

Tenure

₹174,900,000

Compensation

Mr. Umang Vohra, B.E., M.B.A. has been Global Chief Executive Officer, Managing Director and Executive Director of Cipla Limited since September 1, 2016. As Cipla’s MD & GCEO, Mr. Vohra’s priorities have b...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Umang Vohra	MD, Global CEO & Executive Director	7.8yrs	₹174.90m	0.043% ₹ 509.3m
Raju Mistry	President & Global Chief People Officer	5.3yrs	no data	no data
Pradeep Bhadauria	President & Chief Scientific Officer	4.3yrs	no data	no data
Ashish Adukia	Global Chief Financial Officer	1.9yrs	no data	no data
Dinesh Jain	Senior VP & Head of Corporate Finance	no data	no data	no data
Naveen Bansal	Head of Investor Relations	no data	no data	no data
Rajendra Chopra	Compliance Officer & Company Secretary	7.4yrs	₹15.30m	no data
Heena Kanal	Senior Vice-President of Corporate Communications	no data	no data	no data
Anurag Mishra	Head of Cipla Foundation	no data	no data	no data
Kiran Pai	Head of Digital Marketing	7.5yrs	no data	no data
Deepak Viegas	Chief Internal Auditor	no data	no data	no data
Swapn Malpani	Chief Executive Officer of Emerging Markets & Europe	4.3yrs	no data	no data

5.3yrs

Average Tenure

Experienced Management: 500087's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Umang Vohra	MD, Global CEO & Executive Director	7.8yrs	₹174.90m	0.043% ₹ 509.3m
Yusuf Hamied	Non-Executive Chairman	52yrs	₹20.80m	18.64% ₹ 223.3b
Mustafa Hamied	Non-Executive Vice-Chairman	46.9yrs	₹21.00m	3.45% ₹ 41.3b
Ashok Sinha	Independent Non-Executive Director	11yrs	₹9.40m	no data
Punita Lal	Independent Non-Executive Director	9.7yrs	₹6.50m	no data
Adil Zainulbhai	Lead Independent Non-Executive Director	10yrs	₹6.60m	no data
Robert Stewart	Independent Director	3.2yrs	₹10.50m	no data
S. Radhakrishnan	Non-Executive Non-Independent Director	13.7yrs	₹22.10m	no data
Samina Hamied	Non-Executive Director	9yrs	₹92.50m	1.11% ₹ 13.3b
Mandar Vaidya	Independent Director	2yrs	₹4.30m	no data
Prathivadibhayankara Ramesh	Independent Director	3yrs	₹6.80m	no data
Balram Bhargava	Independent Director	less than a year	no data	no data

9.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 500087's board of directors are considered experienced (9.3 years average tenure).

Cipla Management

Management criteria checks 3/4

Key information

Recent management updates

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Recent updates

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Price target increased by 8.7% to ₹1,391

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Full year 2022 earnings: EPS misses analyst expectations

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Cipla Limited Announces Resignation of Kedar Upadhye from the Position of Global Chief Financial Officer

Third quarter 2022 earnings: EPS misses analyst expectations

Cipla Limited and Cipla USA, Inc. Receive Final Approval for Lanreotide Injection

Cipla Limited (NSEI:CIPLA) entered into an agreement to acquire 33% stake in Clean Max Auriga Power LLP for INR 60 million.

Second quarter 2022 earnings released: EPS ₹8.82 (vs ₹8.25 in 2Q 2021)

Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

Full year 2021 earnings released: EPS ₹29.82 (vs ₹19.19 in FY 2020)

Upcoming dividend of ₹5.00 per share

Cipla Receives Final Approval for Generic Version of Sunovion Pharmaceuticals, Inc.'S Brovana® (Arformoterol Tartrate Inhalation Solution 15 Mcg/ 2Ml)

Roche India and Cipla Limited Announces First Batch of the Antibody Cocktail